LABELS · d673c124-d95f-4751-a11a-a26de8740b3a

NebuPent

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-10-15
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups.

Full extracted label fields

application numbers

NDA019887

boxed warning exact

brand names

NebuPent

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

generic names

PENTAMIDINE ISETHIONATE

d673c124-d95f-4751-a11a-a26de8740b3a

indications and usage exact

INDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups.

indications and usage tables exact

is original packager

true

manufacturer names

Fresenius Kabi USA, LLC

matched search terms

sarcoma

package ndcs

63323-877-15

product ndcs

63323-877

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

RESPIRATORY (INHALATION)

rxcuis

861597
861599

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA019887

brand names

NebuPent

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 526
end exclusive: true
exact text: INDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The pat
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 0

current approval status

not_reconciled

duplicate text group

dup-ff1636dc2baac8bda9e4

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-58e14d1f75f679ab3688

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

end: 44
end exclusive: true
exact text: is indicated
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 326
end exclusive: true
exact text: INDICATIONS AND USAGE: NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 .
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 718
end exclusive: true
exact text: cted patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patient
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 127

current approval status

not_reconciled

duplicate text group

dup-a9fded00b9eb0aa7dd38

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-2f217af4fa3713a94174

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 518
end exclusive: true
exact text: These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 327

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 850
end exclusive: true
exact text: /mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assign
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 319

current approval status

not_reconciled

duplicate text group

dup-7a9d052d46fe06323306

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-bf12f8cd128e9d19db66

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 650
end exclusive: true
exact text: The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 519

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA019887

brand names

NebuPent

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1020
end exclusive: true
exact text: and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg ever
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 451

current approval status

not_reconciled

duplicate text group

dup-b09de6fc7de31d8cf28f

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-23a1f1ccfc9307b5bbe7

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

end: 44
end exclusive: true
exact text: is indicated
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 820
end exclusive: true
exact text: The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 651

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1241
end exclusive: true
exact text: one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 621

current approval status

not_reconciled

duplicate text group

dup-e56abc228c88b83fefe8

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-9c23a412fda9bc817b82

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1041
end exclusive: true
exact text: Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139).
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 821

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1432
end exclusive: true
exact text: y assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the tr
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 842

current approval status

not_reconciled

duplicate text group

dup-effb2cb9ddf6d2012d41

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-968f194abfa7c4500d5c

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1232
end exclusive: true
exact text: The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1042

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · risk or warning

application numbers

NDA019887

brand names

NebuPent

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1535
end exclusive: true
exact text: (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1033

current approval status

not_reconciled

duplicate text group

dup-15dbe9204ce148b411f6

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-87f1a0103d0c8802eca9

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1335
end exclusive: true
exact text: The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1233

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 8 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1636
end exclusive: true
exact text: h the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of do
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1136

current approval status

not_reconciled

duplicate text group

dup-37e736bce6568f84e335

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-a434220d35d6fa9b55b8

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1436
end exclusive: true
exact text: A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1336

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1757
end exclusive: true
exact text: 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend to
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1237

current approval status

not_reconciled

duplicate text group

dup-b6740a749cfac36ec1aa

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-21b4e26f9b9a1dadb77e

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1557
end exclusive: true
exact text: The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1437

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1976
end exclusive: true
exact text: s (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1358

current approval status

not_reconciled

duplicate text group

dup-daa1fd0f66989244a57a

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-43b78a4f7c3bc7843394

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1846
end exclusive: true
exact text: The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1558

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA019887

brand names

NebuPent

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1976
end exclusive: true
exact text: portant to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1647

current approval status

not_reconciled

duplicate text group

dup-e637baec81d709c496ca

extraction review status

automated_candidate_pending_source_review

generic names

PENTAMIDINE ISETHIONATE

ind-span-2cc7a4e3e596d6dc8ef8

label id

d673c124-d95f-4751-a11a-a26de8740b3a

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1976
end exclusive: true
exact text: No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups.
label id: d673c124-d95f-4751-a11a-a26de8740b3a
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: b37c35f13bb36d185713cd5ae54e67cb68d1839bcdedc6e3061199c8dc488b9a
start: 1847

source url

https://api.fda.gov/drug/label.json?search=id%3A%22d673c124-d95f-4751-a11a-a26de8740b3a%22

spl effective date

2024-10-15

spl set id

e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice